



Neuroprotective Evaluation of Leaf Extract of *Dalbergia sissoo* in 3-Nitropropionic Acid Induced Neurotoxicity in Rats

Thonda.V.S.S.Swaroop*, Suddhasatwa Banerjee, Handral. M

Department of Pharmacology, PES College of Pharmacy (Rajiv Gandhi University of Health Sciences),
Hanumanthnagar, Bangalore-560 050, Karnataka, India

ABSTRACT

This research was performed to characterize the neuroprotective effect of ethanolic extract of *Dalbergia sissoo* leaves in 3-Nitropropionic acid induced neurotoxic rats. The ethanolic extract of *Dalbergia sissoo* leaves was administered orally at different doses (300 and 600 mg/kg) to neurotoxic rats. During treatment psychopharmacological parameters were recorded, 24 hours after experiment antioxidant profiles from brain isolate were estimated and histopathology of brain was performed. The ethanolic extract significantly attenuated behavioral alterations, oxidative damage, mitochondrial dysfunction, and striatal/hippocampus damage in 3-Nitropropionic acid treated rats. These results suggest that ethanolic extract of *Dalbergia sissoo* leaves may have potential therapeutic value in the treatment of some neurological disorders, probably by its anti-inflammatory, antioxidant and estrogenic properties.

Keywords: 3-Nitropropionic acid, Huntington's disease, Excitotoxicity, Oxidative stress, *Dalbergia sissoo*.

INTRODUCTION

3-Nitropropionic acid (3-NP) is a neurotoxin which is produced by various fungal species and is naturally present in leguminous plants which are commonly used to feed animals and thus also responsible for extensive economic losses in the ranching and cattle industries of the western United States. [1] 3-NP is also associated with an epidemic of acute encephalopathy in children who ate moldy sugarcane containing 3-NP, which was reported for the first time in China in 1980. The children exposed to 3-NP developed gastrointestinal disturbance followed by encephalopathy and coma, with dystonia and choreiform movements in survivors. [2] In animals, decreased motor performance with lesions primarily in the striatum, but also in hippocampus and thalamus was reported. [3] 3-NP is an irreversible inhibitor of the electron transport enzyme succinate dehydrogenase, a mitochondrial Complex II enzyme responsible for the oxidation of succinate to fumarate in Krebs cycle. Subsequently it blocks the transport of electrons in oxidative phosphorylation, causing ATP levels in the brain to fall. [4-5] Normally brain requires the highest amount of energy, and this toxin thus affects normal brain electrical activity. Oxidative stress has been suggested to play a role in 3-NP

toxicity; however, the process behind the oxidative damage is not fully understood. [6] 3-NP was found to act on NMDA receptors thereby inducing excitotoxicity and leading to generation of free radicals. The inflammation associated with 3-NP, also acts as a contributing factor for neuronal damage and free radical generation. 3-NP is one of the several mitochondrial toxins which were used as model for HD. [7-8] Numerous reports have suggested that mitochondrial energy impairment is related to Huntington disease. [7] *In-vivo*, intrastriatal injection of mitochondrial toxin in rats produce excitotoxic lesions, while chronic administration of 3-NP produces excitotoxic-like lesions regionally restricted to striatum in both rats and non-human primates. [2, 5] The changes are similar to the changes described in the HD striatum. [9]

Pharmaceutical approach for novel prevention and treatment strategies of neurodegeneration involves the use of neuroprotective agents in order to delay or stop neuronal cell death or to strengthen cellular defense system. But effective therapies still remain elusive. [10] A number of natural compounds are being used as brain tonic to help restore debilitated conditions. Since plants produce significant amount of antioxidants, they represent a potential source of new compounds with antioxidant activity. In view of this, *Dalbergia sissoo* Roxb. has been selected based on its use in traditional systems of medicine for augmenting neurological health and was reported to be brain tonic [11], which appear to offer very promising outcomes for neuroprotection. *Dalbergia sissoo* Roxb. (family-fabaceae) also called

*Corresponding author: Mr. Thonda.V.S.S.Swaroop,
Department of Pharmacology, PES College of Pharmacy
(Rajiv Gandhi University of Health Sciences),
Hanumanthnagar, Bangalore-560 050, Karnataka, India; Tel.: +91-7411529428; E-mail: swaroop.pharam90@gmail.com

'shisham' is used time immemorial for treatment of various ailments like burning sensations, dysentery, dyspepsia, leucoderma, and skin ailment, anti-inflammatory, memory enhancer and leaves have significant levels of flavonoids which showed antioxidant activity twice of commonly used antioxidants like vitamin C and selenium.^[12] It possesses antioxidant and prevents central nervous system damage^[11] however the effectiveness of *Dalbergia sissoo* in controlling 3-NP induced excitotoxicity is not carried out. The present study aims to evaluate the effect of ethanolic leaf extract of *Dalbergia sissoo* in chemically induced neurotoxic rats. Antioxidant, anti-inflammatory and estrogenic activities of the plant may be responsible for its neuroprotective effect.

MATERIALS AND METHODS

Drugs and chemicals

Trichloroacetic acid (TCA), 2 thiobarbituric acid (TBA), 5-5-dithiobis (2-nitrobenzoic acid) (DTNB), Phenazine methosulphate, Nicotinamide adenine dinucleotide (NADH), Nitro blue tetrazolium (NBT), 3-Nitropropionic acid (3-NP) were purchased from Sigma-Aldrich, USA. All other chemicals were of the highest purity commercially available.

Plant material and extraction

The fresh leaves of *Dalbergia sissoo* Roxb, were collected from Gandhi Krishi Vignan Kendra (GKVK) Karnataka, India in the month of July 2012. The plant was identified and authenticated by Mr. KP Sreenath, taxonomist Department Botany, Bangalore University, Bangalore, India.

The collected fresh leaves were shade dried or tray dried for two weeks and then grinded to a fine powder. In the continuous hot extraction method, the plant leaves powder was extracted in ethanol for 3 days at temperature of 78-80°C. The mixture was subsequently filtered and concentrated under reduced pressure at 40°C in rotary flush evaporator. The extract yield was 26% w/w.^[13] The extract was stored in desiccator.

Preparation of *Dalbergia sissoo* leaf extracts suspension

Weighed quantity of ethanolic leaf extract of *Dalbergia sissoo* was suspended in distilled water using 0.5% v/v Dimethyl sulphoxide and administered orally to rats. The suspension of extract was prepared freshly every day. The extract was administered at a constant volume of 1 ml for each animal.^[14]

Preliminary Phytochemical Investigation

The extracts were used for preliminary phytochemical screening with a battery of chemical tests viz., Molisch's, Fehling's, Benedicts and Barfoed's test for carbohydrates; Biuret and Millon's tests for proteins; Ninhydrin's test for amino acids; Salkowski and Libermann-Burchard's reactions for steroids; Borntrager's test for anthraquinone glycosides; Foam test for saponin glycosides; Shinoda and alkaline tests for flavonoids glycosides; Dragendorff's, Mayer's, Hager's and Wagner's tests for alkaloids; and ferric chloride, Lead acetate tests for tannins and phenols.^[15]

Animals

Adult female Wistar rats (180-220 g) bred in animal house of PES College of Pharmacy, Bangalore, were used. The animals were procured from Ragavendra enterprises, Bangalore maintained on a 12 h light: 12 h dark cycle and free excess of food and water. Animals were acclimatized to laboratory conditions before the test. The experimental protocols were approved by the Institutional Animal Ethics Committee (PESCP/IAEC/02/11, Dated 14/12/11) and conducted according to CPCSEA guidelines, Govt. of India.

Acute oral toxicity studies

Acute toxicity studies were carried out on mice according to method proposed by Ghosh, alcoholic leaf extracts at dose of 50, 100, 300, 1000, and 3000 mg/kg body weight were administered to separate groups of the mice (n=6) after overnight fasting. Subsequent to administration of ELDS, the mice observed closely for the first 3 hours for toxic manifestations like increased motor activity, salivation, clonic convulsions, coma and death. The observations were made at regular intervals for 24 hours. The animals were observed for 1 week. The study revealed that ELDS was not toxic up to 3000 mg/kg body weight.^[16]

Treatment

3-NP was diluted with saline (adjust pH 7.4) and administered intra-peritoneal to rats for period of 7 days to induce the toxicity. Total 30 rats were randomly divided into five groups of 6 rats each and treated as follows.^[17]

Control group: Receives 1ml of vehicle (0.5% DMSO) alone for 7 days (p.o), from 8th day onward vehicle (0.5% DMSO) followed by 0.5 ml of normal saline (i.p) after 2 hours daily up to 14 days.

3-NP inducing group: Receives 0.5 ml of normal saline alone for 7 days (p.o), from 8th day onward saline followed by 0.5 ml of 3-NP 10 mg/kg (i.p) after 2 hours daily up to 14 days.

ELDS (600 mg/kg) + Normal saline (NS) group: Pretreatment for 7 days with 1ml of ELDS 600 mg/kg for 7 days (p.o), from 8th day onward ELDS 600 mg/kg followed by 0.5 ml of normal saline (i.p) after 2 hours daily up to 14 days.

ELDS (300 mg/kg) + 3-NP group: Pretreatment for 7 days with 1ml ELDS 300 mg/kg (p.o), from 8th day onward ELDS 300 mg/kg followed by 0.5 ml of 3-NP 10 mg/kg (i.p) after 2 hours daily up to 14 days.

ELDS (600 mg/kg) + 3-NP group: Pretreatment for 7 days with 1 ml of ELDS 600 mg/kg (p.o) from 8th day onward ELDS 600 mg/kg followed by 0.5 ml of 3-NP 10 mg/kg (i.p) after 2 hours daily up to 14 days.

The gap between 3-NP and ELDS administration is 2 h. The dose of 3-NP and ELDS is selected based on previous literature.^[17] During the drug treatment rats were observed for the behavioral changes for 50 min daily. On 14th day after 4 h of 3-NP administration rats were evaluated for neurological scoring, ambulatory behavior, elevated plus maze test, Rota rod performance and hanging wire test. On 15th day, elevated plus maze test was performed and rats were sacrificed and brain were isolated for estimation of GSH, CAT, LPO, SOD and total protein, histopathological study.

Parameters monitored

Measurement of body weight change

Animal body weight was noted on the first day and last day of the experimentation. Percentage change in body weight was calculated in comparison to the initial body weight on the first day of the experimentation.^[18]

Behavioral parameters

Movement analysis

Neurotoxins are associated with several motor disturbances which prevent normal ambulatory movement of the animal. Severity of the motor abnormalities in these groups was therefore evaluated using a quantitative neurological scale. A neurological score was determined for each animal on 14th day after 4 h of last dose in comparison to control animals.

(Score = 0, normal behavior; score = 1, general slowness of displacement resulting from mild hind limb impairment; score = 2, in coordination and marked gait abnormalities; score = 3, hind limb paralysis; score = 4, incapacity to move resulting from fore limb and hind limb impairment; score = 5, recumbency).^[18-19]

Locomotor activity

The spontaneous loco motor activity was monitored using photo actometer (INCO Pvt. Ltd., Ambala, India) equipped with infrared sensitive photocells, the apparatus was placed in darkened, light and sound attenuated and ventilated testing room. Before loco motor task, animals were placed individually in the activity meter for 2 min for habituation. Thereafter, locomotor activity was recorded for a period of 5 min. The locomotor activity was expressed in terms of total photo beam counts/ 5 min.^[20]

Elevated plus maze test for special memory

Memory dysfunction is evaluated using elevated plus maze, which consists of two opposite open arms (50 cm × 10 cm), crossed with two closed arms of same dimensions with 40 cm high wall. The arms are connected with Central Square (10 cm × 10 cm). Acquisition of memory was assessed on day 7th after initiating 3-NP treatment. Rat was placed individually at one end of an open arm facing away from the central square. The time taken by animal to move from open arm and enter in to one of the closed arm was recorded as initial transfer latency (ITL). Rat was allowed to explore the maze for 30 s after recording ITL and returned to its home cage. Retention transfer latency (RTL) was noted again on 8th day of first 3-NP dose. The percent retention of memory was calculated by the formula. Similarly the activity was repeated in 14th and 15th day.^[21]

$$\% \text{ Memory retention} = (\text{ITL} - \text{RTL}) / \text{RTL} \times 100$$

Rota-rod performance assessment for motor coordination

The rota rod (rotating rod) test is widely used in rodents to assess their “minimal neurological deceit” such as impaired motor function (e.g., ataxia) and coordination. The Rota rod unit consists of a rotating rod, 75mm in diameter, which was divided into four parts by compartmentalization to permit the testing of four rats at a time. Briefly, in a training session, the rats were placed on the rod that was set to 25 rpm and the performance time that each rat was able to remain on the rota rod was recorded. The rats were subjected to three training trials at 3 to 4 hours intervals on two separate days for acclimatization purposes. In the test session, the rats were placed on the rota rod and their performance times were recorded.^[22]

String test for grip strength

The rat was allowed to hold with the forepaws a steel wire (2 mm diameter and 80 cm in length), placed at a height of 50 cm over a cushion support. The length of time the rat was able to hold the wire was recorded. This latency to the grip loss is considered as an indirect measure of grip strength cut off time was taken as 90 s.^[23]

Animal autopsy and isolation of brains

After the treatment period, experimental and control mice were sacrificed by decapitation under mild anesthesia. Brains were immediately isolated, rinsed in ice cold saline to remove blood and stored at -20°C immediately until used in assays described below.

Estimation of antioxidant enzyme levels in brain tissue

Preparation of tissue homogenate: The whole brain dissected out, blotted dry and immediately weighed. The

brain regions cerebral cortex (Ct), cerebellum (Cb), hippocampus (Hc) and striatum (St) were subsequently dissected from the intact brain carefully on ice plate ($4 \pm 2^\circ\text{C}$). A 10% brain homogenate was prepared with ice-cold phosphate buffered saline (0.1 M, pH 7.4) using Teflon-glass homogenizer. The homogenate was centrifuged at 10,000 rpm at -4°C for 15 min and the pellet discarded. The supernatant obtained was used for the quantification of antioxidant levels like GSH, CAT, LPO, SOD, total protein levels.^[24]

Catalase (CAT)

In brief, the incubation mixture contained 0.1 ml of diluted homogenate, 1.0 ml of phosphate buffer and 0.4 ml of distilled water to which 0.5 ml of H_2O_2 solution was added to initiate the reaction, while the H_2O_2 solution was left out in control tubes. After incubating for 1 min at 37°C the reaction was stopped by addition of 2 ml of potassium dichromate acetic acid reagent. The samples were kept in boiling water bath for 15 minutes, finally cooled and the absorbance measured at 570 nm against control. The catalase content was calculated by using molar extinction coefficient = $58.03 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$ and the values are expressed as nmoles/mg protein.^[25]

Lipid peroxidation (LPO)

Briefly, the reaction mixture contained 0.1 ml of brain regions homogenate (1 mg protein), 1.5 ml of 20% acetic acid (pH 3.5), 1.5 ml of 0.8% thiobarbituric acid (0.8 % w/v) and 0.2 ml Sodium dodecyl sulphate. Following these additions, tubes were mixed and heated at 95°C for one hour on a water bath and cooled under tap water before mixing 1 ml of distilled water and 5 ml mixture of n-butanol and pyridine (15:1). The mixture was centrifuged at 2200 g for 10 min. The amount of MDA/TBARS formed was measured by the absorbance of upper organic layer at a wave length of 532 nm. The results are expressed as nmol MDA/mg protein. The absorbance of the clear pink color supernatant was measured at 532 nm against appropriate blank. The amount of lipid peroxidation was determined by using molar extinction coefficient $1.56 \times 10^5 \text{ M}^{-1} \text{ cm}^{-1}$ and the results were expressed as nmoles MDA/g of protein.^[26]

Reduced Glutathione (GSH)

The assay is based on the principle of Ellman's reaction. The sulfhydryl group of glutathione reacts with DTNB (5, 5'-dithiobis-2-nitrobenzoic acid) and produces a yellow colored 5-thio- 2-nitrobenzoic acid (TNB). Measurement of the absorbance of TNB at 412 nm provides an accurate estimation of glutathione in a sample. Briefly, 0.5 ml of homogenate is mixed with 0.1 ml of 25% TCA to precipitate proteins and centrifuged at 4000 rpm for 5 min. Then 0.3 ml of the supernatant was mixed with 0.5 ml of 0.1M phosphate buffer (pH 7.4) and 0.2 ml of 10 mM DTNB. This mixture was incubated for 10 min and the absorbance was measured at 412 nm against appropriate blanks. The glutathione content was calculated by using extension coefficient $13.6 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$. The values are expressed as nmoles/mg protein.^[27]

Super oxide dismutase (SOD)

The assay mixture contained 0.1 ml of sample, 1.2 ml of sodium pyrophosphate buffer (pH 8.3, 0.052M), 0.1 ml of phenazine methosulphate (186µm), 0.3 ml of nitro blue tetrazolium (300µm), 0.2 ml of NADH (750µm). Reaction was started by addition of NADH. After incubation at 300°C for 90 sec, the reaction was stopped by the addition of 1 ml

of glacial acetic acid. The mixture was allowed to stand for 10 min. The color intensity of the chromogen was measured at 560 nm against blank and concentration of SOD was expressed as units/min/mg of protein. [28-29]

Total protein (TP)

The total protein of brain tissue was determined by biuret method in ERBA diagnostic kit. [30-31]

Total protein (g/dl) = Absorbance of test/Absorbance of standard*concentration of standard (g/dl)

Histopathological study of rat brain

A section of the brain was fixed with 10% formalin and embedded in paraffin wax and cut into sections of 5µm thickness. The sections were stained with haematoxylin and eosin dye for histopathological observations. Depending on the model, either hippocampal or striatal neurons were observed for morphological changes. [32]

Statistical evaluation

The data were expressed as Mean ± S.E.M. Statistical comparisons were performed by one way ANOVA followed by Tukey's post-test using Graph Pad Prism version 5.0. * $P<0.05$, ** $P<0.01$, *** $P<0.001$ will be considered as significant compared to toxic control.

Table 1: Observation table of Chemical tests

S. No	Tests	Present{+}/Absent(-)
1.	Carbohydrates	
	Molish's test	+
	Benedict's test	+
	Fehling's test	+
	Barfoed's test	+
2.	Proteins	
	Biuret test	+
	Millon's test	+
3.	Amino acids	
	Ninhydrin's test	+
4.	Steroids	
	Salkowski reaction	+
	Liebermann-burchard's reaction	+
5.	Flavonoid glycosides	
	Shinoda test	+
	Alkaline test	+
6.	Anthraquinone glycosides	
	Borntrager's test	+
7.	Saponin glycosides	
	Foam test	+
8.	Alkaloids	
	Dragendorff's test	-
	Mayer's test	-
	Hager's test	-
	wagner's test	-
9.	Tannins and phenols	
	Ferric chloride test	+
	Lead acetate test	+

RESULTS

Phytochemical analysis

Phytochemical study Extract subjected for phytochemical study showed the presence of carbohydrates, proteins, amino acids, steroids, phenolic compounds, tannins, glycosides and flavonoids (Table 1).

Acute toxicity studies

The ethanolic extract did not show any signs and symptoms of toxicity and mortality up to 3000 mg/kg dose.

Monitored Parameters

Effect of ELDS on Body weight change in 3-NP induced neurotoxicity in rats

Administration of 3-NP (10 mg/kg i.p. for 7 days) resulted in change in body weight when compared to normal rats. In case of 3-NP induced rats, the body weight was significant

($P<0.001$) decreased initial body weight. Treatment with ELDS (300 and 600 mg/kg p.o.) markedly prevented the 3-NP induced decrease in body weight. The effect of ELDS at 300 mg/kg was found to be much better ($P<0.05$) than its higher dose when compared to 3-NP control (Table 2).

Effect of ELDS on Behavioral characters in 3-NP induced neurotoxicity in rats

Neurological scoring

Intra-peritoneal administration of 3-NP resulted in significant ($P<0.001$) motor abnormalities, out of six rats three rats showed in-coordination and hind limb paralysis, two rats showed hind limb and forelimb paralysis and one rat showed marked gait abnormalities. They showed increase neurological score when compared to normal control rats. Pretreatment with ELDS (300 and 600 mg/kg) in 3-NP induced rats showed a significant ($P<0.001$ and $P<0.01$) improvement in behavioral changes when compared to 3-NP induced rats (Table 2).

Locomotor activity

Administration of 3-NP from 8-14 days resulted in significant ($P<0.01$) decrease in locomotor activity when compared to normal control animals. Animals pretreated with ELDS (300 and 600 mg/kg) in 3-NP induced rats prevented significantly ($P<0.05$) decreased locomotor activity compared to control animals (Table 2).

Hanging wire test

Animals treated with 3-NP from 8-14 days resulted in significantly ($P<0.001$) decrease in grip strength when compared to normal control animals. Pretreatment with ELDS (300 and 600 mg/kg) in 3-NP induced rats improved significantly ($P<0.001$ and $P<0.05$) the grip strength compared to 3-NP alone treated rats (Table 2).

Elevated plus maze paradigm

In the present experiment, mean initial transfer latency (ITL) on day 14th day was relatively stable in all the animals within the group. 3-NP alone administered rats for 7 days showed significant ($P<0.001$) increase in mean retention transfer latency (RTL) compared to normal control animals. Normal control animals entered closed arm quickly and mean RTL was shorter when compared to its own ITL (initial transfer latency). In contrast, 3-NP treated rats performed poorly and showed an increased mean RTL compared to its own ITL. This indicates there is cognitive dysfunction in 3-NP treatment. Chronic pretreatment with ELDS (300 and 600 mg/kg p.o.) to 3-NP treated rats showed significant ($P<0.01$) improvement in memory performance when compared to 3-NP alone treated rats (Table 2).

Rota rod test

Administration of 3-NP from 8-14 days significantly ($P<0.001$) decreased motor coordination and body balance when compared to normal control rats. Pretreatment with ELDS (300 and 600 mg/kg) in 3-NP induced rats significantly ($P<0.001$ and $P<0.01$) improved the motor coordination and body balance and showed increase in latency to balance on the beam (Table 2).

Antioxidant Parameters

Effect of ELDS on levels of CAT, LPO, GSH, SOD, and TP:

Results clearly revealed increase in the levels of MDA and hydroperoxides in 3-NP induced toxic group compared to control group. Treatment with extracts significantly prevented this rise in levels. CAT, GSH, SOD and TP content have significantly increased in extract treated groups whereas toxic group has shown significant decrease in levels

Table 2: Effect of ELDS on Body weight change and Behavioral characters in 3-NP induced neurotoxicity in rats

Treatment	% Body weight change	Neurologic al score	Locomotor activity (counts/5min)	Grip strength test (s)	Plus maze(transfer latency time sec)	Plus maze (% memory retention)	Rotarod performance (s)
Normal control group	101.6 ^a	0.0 ^a	360±21.21 ^b	27.80±2.28 ^a	10.43±1.98	78.20	28.80±0.96 ^a
Inducing group (3-NP)	83.24	3.0±0.31	178.0±8.0	12.40±1.24	18.15±0.87	43.20	16±1.22
High dose (D.S 600 mg/kg)+NS	98.23	0.0 ^x	432.0±48.21	35.40±2.31 ^z	10.21±0.76	72.30	29.80±1.15
Low dose (D.S 300 mg/kg)+3-NP	95.24 ^c	1.40±0.24 ^a	318±26.15 ^c	27.20±0.73 ^a	8.90±1.87	68.40	26.20±0.80 ^a
High dose(D.S 600 mg/kg)+3-NP	94.33 ^c	2.20±0.37 ^b	310.0±24.29 ^c	20.80±1.74 ^c	13.94±1.07	57.80	25.0±0.89 ^b

Each value are expressed as mean ± SEM (n = 6), ^a $P < 0.001$, ^b $P < 0.01$, ^c $P < 0.05$ when compared to 3-NP alone treated rats. ^x $P < 0.001$, ^y $P < 0.01$, ^z $P < 0.05$ when compared to control rats. One-way ANOVA followed by Tukey's post test


Table 3: Effect of ELDS on antioxidant levels in 3-NP induced neurotoxicity in rats

Treatment	Catalase ($\mu\text{m H}_2\text{O}_2/\text{min/mg}$ of protein)	Lipid peroxidation (nmoles of MDA/g protein)	Reduced glutathione (nmoles/min/mg of protein)	Super oxide dismutase (units/min/mg of protein)	Protein estimation (g/dl of total protein)
Normal control group	55.10±3.04 ^b	96.65±6.36 ^a	3.16 ±0.33	16.24±0.09 ^a	8.81±0.41 ^c
Inducing group (3-NP)	22.69±1.98	713.9±81.60	1.10±0.75	10.25±0.02	5.46±0.44
High dose (D.S 600 mg/kg)+NS	59.18±3.60	93.29±5.33	3.16±0.17	15.79±0.55	9.23±0.39
Low dose (D.S 300 mg/kg)+3-NP	44.79±3.71 ^c	133.1±10.44 ^a	2.55±0.26	14.31±0.41 ^b	6.77 ±0.43
High dose(D.S 600 mg/kg)+3-NP	42.95±1.51 ^c	151.2±8.60 ^a	1.98±0.17	12.33±0.10 ^c	8.02±0.60

Each value are expressed as mean ± SEM (n = 6), ^a $P < 0.001$, ^b $P < 0.01$, ^c $P < 0.05$ when compared to 3-NP alone treated rats. ^x $P < 0.001$, ^y $P < 0.01$, ^z $P < 0.05$ when compared to control rats. One-way ANOVA followed by Tukey's post test


compare to control group. Ethanolic extract (300mg/kg) has shown maximum protection (Table 3).

Histopathology




A. Control group

B. 3-NP Inducing group



C. Low dose ELDS (300mg/kg)+3-NP



D. High dose ELDS (600mg/kg)+3-NP

E. High dose ELDS (600mg/kg)+NS

Histopathological observations of hippocampal region in 3-NP induced neurotoxicity in rats

- Control group:** The CA3 region shows intact pyramidal cells in tight clusters [Fig. A(I), Arrow]. The interconnected neuropil fibers in CA3 region appear intact. The CA1 region shows intact pyramidal cells [Fig. A(II), Long Arrow] along with intact neuropil fibres [Fig. A(II), Short Arrow].
- 3-NP inducing group:** The CA3 region shows intact pyramidal cells in clusters [Fig. B(I), Arrow]. The interconnected neuropil fibers in CA3 region appear intact. The CA1 region shows decreased number of intact pyramidal cells and most of the pyramidal cells show degenerative changes [Fig. B(II), Long Arrow] along with decrease in neuropil fibres [Fig. B(II), Short Arrow].
- Low dose ELDS (300 mg/kg) +3-NP:** The CA3 region shows few intact pyramidal cells [Fig. C(I), Short Arrow] and damaged pyramidal cells [Fig. C(I), Long Arrow] with dense inflammatory cells. The interconnected neuropil fibers in CA3 region appear reduced. The CA1 region shows few intact pyramidal cells [Fig. C(II), Short Arrow] and pyramidal cells show degenerative changes [Fig. C(II), Long Arrow] along with dense inflammatory cells and reduced neuropil fibres.
- High dose ELDS (600 mg/kg) +3-NP:** The CA3 region shows some intact pyramidal cells in clusters [Fig. D(I), Short Arrow] and some damaged pyramidal cells [Fig. D(I), Long Arrow]. The interconnected neuropil fibers in CA3 region appear intact. The CA1 region shows moderate number of intact pyramidal cells and some of the pyramidal cells show degenerative changes [Fig. D(II), Long Arrow] along with intact neuropil fibres [Fig. D(II), Short Arrow].

- E. High dose ELDS (600 mg/kg) + NS:** The CA3 region shows intact pyramidal cells [Fig. E(I), Short Arrow] and some damaged pyramidal cells [Fig. E(I), Long Arrow]. The interconnected neuropil fibers in CA3 region appear reduced. The CA1 region shows pyramidal cells and few of the pyramidal cells show degenerative changes [Fig. E(II), Arrow] along with decreased neuropil fibres.

DISCUSSION

3-NP toxic model is one of the important models offering inferential information on those toxic events occurring in Huntington's disease (HD). The treatment of rats with 3-NP was produced significant motor and behavioral abnormalities including bradykinesia, muscles weaknesses and rigidity. These findings are in agreement with earlier report who also observed a variety of neurobehavioral abnormalities and motor deficit in rats following 3-NP administration.^[33] The symptoms developed by sub chronic administration of 3-NP are akin to juvenile onset and late hypokinetic stages of HD.^[34] In the present study, sub-chronic administration of 3-NP for 7 days produced significant alterations in body weight change, motor and cognition related behaviors. The weight reduction was not shown by the animals which were treated with ELDS. This reduction in weight could be due to metabolic impairment caused by 3-NP, i.e. impairment in energy metabolism, mobilization of energy stores and lipid peroxidation which constitute peripheral effects.^[33-34] However, striatal lesions and bradykinesia must be acting as central contributing factors for weight loss.^[18, 35]

3-NP administration can cause both hypoactivity and hyperactivity depends on frequency and time of dosing.^[18, 34] Animals which received 3-NP for 7 days exhibited significant hypoactivity along with marked neuronal loss in the dorsolateral striatum depicting that rigidity and movement disorders are related to basal ganglia lesions.^[34] In the present study, ELDS pretreatment improved the hypoactivity, as evident by several behavioral investigations such as movement analysis and locomotor activity. It was also observed that there was significant increase in transfer latency of animals in elevated plus maze test in 3-NP administered rats. 3-NP administration in early reports also showed cognitive deficit, motor deficit and hypokinetic activity which resembles clinical symptom related to HD.^[34-35] Pretreatment and treatment with both the doses of ELDS significantly protected the 3-NP induced increase in transfer latency on elevated plus maze and behavior and motor deficit.

The involvement of oxidative damage and mitochondrial dysfunction are implicated in 3-NP toxicity along with possible involvement of excitotoxicity and generation of free radicals due to glutamate release.^[33] This increased glutamate causes influx of Ca^{+2} and may lead to superoxide production and activation of calcium-dependent nitric oxide synthase, causing an increase in oxidative and nitrosative stress activation.^[34-35] In the present study, administration of 3-NP for 7 days, produced oxidative stress (increased levels of LPO (as evident by increased MDA levels) and depleted levels of endogenous antioxidant enzyme (catalase, reduced glutathione, SOD levels). These results supports the oxidative stress based theory of neurotoxicity caused by 3-NP.^[33] The mitochondrial dysfunction due 3-NP leads to decreased level of succinic dehydrogenase (SDH), which is

believed to be major mechanism of 3-NP toxicity. In the present study, we could not able measure the levels of SDH, but however, several articles supports hypothesis of depletion.^[17] It is well documented that polyphenol and flavonoid content of stem bark extracts is significantly more and having antioxidant activity and leaf extract possess anti-inflammatory activity which is due to bioactive flavonoids found in the leaf extract. On the other hand treatment with ELDS has significantly reversed the 3-NP induced changes. However, treatment with the low dose of ELDS has produced more significant reversal of catalase, GSH, SOD than high dose, reason could not establish this study, and however the LPO produces similar changes suggesting the possible involvement of antioxidant action of ELDS in preventing 3-NP neurotoxicity. This activity is comparable with anti-inflammatory activity of leaf extract of *Dalbergia sissoo* due antioxidant activity.^[36] Taken together; these results suggest that its antioxidant properties might be one of the contributing factors to its neuroprotectant action. 3-NP induced neurotoxicity there is a direct relationship of inflammation and excitotoxicity, due to various inflammatory mediators and glutamate induced excitotoxin activation results in neuronal death.^[36-37] Extracts of related species, *D. odorifera* is known to inhibit inflammation via Cyclooxygenase-2 which could be other factor in providing protection.^[36, 38] The observed results leading to neurodegeneration is also confirmed by the histopathological differences between treatment and 3-NP control group. There was a reversal of the brain damage observed in ELDS treated animals and it prevented the neuron loss.

Hence it can be concluded that ELDS protected 3-NP induced neurodegeneration attributed to its antioxidant and behavioral properties. The study also suggests that the protection of antioxidant enzymes activity along with the direct antagonism of 3-NP may be beneficial. This activity of *Dalbergia sissoo* can be further explored in stroke, epilepsy and other degenerative conditions in which the role of glutamate and inflammatory mediators known to play vital role in the pathogenesis.

REFERENCE

1. Alston TA, Mela L, Bright HJ. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. *Proc Natl Acad. Sci.* 1977; 74: 3767-3771.
2. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM. Neurochemical and histological characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. *J Neurosci.* 1993; 13: 4181-4192.
3. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri, M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. *Can. J Neurol Sci.* 1991; 18: 492-498.
4. Coles CJ, Edmondson DE, Singer TP. Inactivation of succinate dehydrogenase by 3-nitropropionate. *J Biol Chem.* 1979; 254: 5161-5167.
5. Brouillet E, Guyot MC, Mittoux V, Altairac, S, Conde F, Palfi S. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. *J Neurochem.* 1998; 70: 794-805.
6. Schulz JB, Henshaw DR, MacGarvey U, Beal MF. Involvement of oxidative stress in 3-nitropropionic acid neurotoxicity. *Neurochem Int.* 1996; 29:167-171.
7. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? *Ann Neurol.* 1992; 31: 119-130.
8. Fontaine MA, Geddes JW, Banks A, Butterfield DA. Effect of exogenous and endogenous antioxidants on 3-nitropropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. *J Neurochem.* 2000; 75: 1709-1715.

9. Guyot MC, Hantraye P, Dolan R, Palfi S, Maziere M, Brouillet E. Quantifiable bradykinesia, gait abnormalities, and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. *Neuroscience*. 1997; 79: 45-56.
10. Matthias L, Reichmann H. Clinical neuroprotection in Parkinson's disease- still waiting for the breakthrough. *J Neurol Sci*. 2010; 289: 104-114.
11. Madhava chetty K, Sivaji K, Tulasi rao K. Flowering plants of chittoor district Andhra Pradesh, India. Edn 1, Students offset printers, Tirupati, 2008, pp 88.
12. Mukhtar HS, Irum M, Khan SN. Medicinal importance and association of pathological constraints with *Dalbergia sissoo*. *Pak J Phytopathol*. 2010; 22(2): 135-138.
13. Pankaj SN, Dharmendra S, Kiran P, K J. Antidiabetic activity of ethanolic extract of *Dalbergia sissoo* L. Leaves in alloxan-induced diabetic rats. *ijcpr*. 2010; 2(2): 24-27.
14. Adedotun AA, Alexander BO. Laboratory assessment of molluscicidal activity of crude aqueous and ethanolic extracts of *Dalbergia sissoo* plant parts against *Biomphalaria pfeifferi*. *TMAID*. 2008; 6: 219-227.
15. Josephin NR, Venkatarathnakumar T, Gowra R, Raadhika K et.al. Pharmacognostic and preliminary phytochemical evaluation of the leaves of *Dalbergia sissoo* Roxb. *Asian J Pharm Clin Res*. 2012; 5(3): 115-119.
16. Ghosh MN. Fundamental of experimental pharmacology. 3rd ed. Mumbai: Hilton and Company; 2005.
17. Puneet K, Kumar A. Effects of root extract of *Withania somnifera* in 3- Nitropropionic Acid-Induced Cognitive Dysfunction and Oxidative Damage in Rats. *Int J Health Res*. 2008; 1(3): 139-149.
18. Manuj A, Mahendra B, Chopra K. Protective effect of minocycline, a semi synthetic second-generation tetracycline against 3-nitropropionic acid(3-NP)-induced neurotoxicity. *Toxicology*. 2008; 244: 111-122.
19. Chao G, Li T, Miaomaio X, Haifan Y, Hailong D. Neuroprotective effect of calycosin on cerebral ischemia and reperfusion injury in rats. *J Ethnopharmacol*. 2012; 144: 768-774.
20. Shalavandl MH, Chandrasekhar VM, Avinash SP, Sowmya c, et.al. Neuroprotective activity of *stereospermum suaveolens* DC against 6-OHD induced Parkinson's model. *Indian J Pharmacol*. 2012; 44(6): 737-743.
21. Puneet K, Kumar A. Protective role of sertraline against 3-nitropropionic acid-induced cognitive dysfunction and redox ratio in striatum, cortex and hippocampus of rat brain. *Indian J Exp Biol*. 2009; 47: 715-722.
22. Moshahid KM, Ajmal A, Tauheed I, Badruzzaman K, Nasrul H M, et.al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. *Brain Res*. 2010; 1328: 139-151.
23. Nicolas A, Gillet JP, Fialip J, Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. *Expl Neurol*. 2003; 182: 12-20.
24. Sandeep K, Usha KM, Jayantee K, Vinay KK, Yahiya KM. Imbalance in oxidant/antioxidant system in different brain regions of rat after the infection of Japanese encephalitis virus. *Neurochem Int*. 2009; 55: 648-654.
25. Anil kumar MD, Inamdar NM. Evaluation of beneficial effects of antioxidant properties of aqueous leaf extract of *andrographis paniculata* in STZ-induced diabetes. *Pak J Pharm Sci*. 2009; 22: 49-52.
26. Hiroshi O, Nobuko O, Yagi K. Assay for Lipid Peroxides in Animal Tissues by Thiobarbituric Acid Reaction. *Anal Biochem*. 1979; 95: 351-358.
27. Ellman GL. Tissue Sulphydryl Groups. *Arch Biochem Biophys*. 1959; 82: 70-77.
28. Deepak KD, Veerendra CY, Siva SN, Tirtha G, Rajalingam D, et.al. Evaluation of hepatoprotective and antioxidant activity of *Ichnocarpus frutescens* (Linn.) R.Br. on paracetamol-induced hepatotoxicity in rats. *Trop J Pharm Res*. 2007; 6(3): 755-765.
29. Anusha J, Flora SJ. Dose related effects of nicotine on oxidative injury in young, adult and old rats. *J. Environ. Biol*. 2012; 33: 233-238.
30. Young DS, Pestaner LC, Gibberman V. Effects of drugs on clinical laboratory tests. *Clin. Chem*. 1975; 21: 351-353.
31. Friedman RB, Anderson RE, Hirshberg SB. Effects of diseases in clinical laboratory tests. *Clin.Chem*. 1980; 26: 209-211.
32. Chandrashekhar VM, Ranipariya VL, Ganapaty S, Parashar, Muchandi AA. Neuroprotective activity of *Matricaria recutita* Linn against global model of ischemia in rats. *J Ethnopharmacol*. 2010; 127: 645-651.
33. Tariq M, Khan HA, Elfaki I, Deeb SA, Moutaery KA. Neuroprotective effect of nicotine against 3-nitropropionic acid induced experimental Huntingtons disease in rats. *Brain Res Bull*. 2005; 67: 161-168.
34. Tunez I, Inmaculada T, Perez-De La Cruz V, Santamaria A. 3-Nitropropionic Acid as a Tool to Study the Mechanisms Involved in Huntington's Disease: Past, Present and Future. *Molecules*. 2010; 15: 878-916.
35. Kumar P, Kumar A. Neuroprotective effect of cyclosporine and FK506 against 3 nitropropionic acid induced cognitive dysfunction and glutathione redox in rat: possible role of nitric oxide. *Neurosci Res*. 2009; 63: 302-314.
36. Hajare SW, Chandra S, Sharma J, Tandan SK, Lal J et al. Anti-inflammatory activity of *Dalbergia sissoo* leaves. *Fitoterapia*. 2001; 72: 131-139.
37. Kamal H, Shaltout, Keshta AE. The biology of Egyptian woody perennials. *Ass.Univ.Environ.Res*. 2011; 14(2): 132-153.
38. Hajare SW, Chandra S, Tandan SK et al. Analgesic and Antipyretic activities of *Dalbergia sissoo* leaves. *Indian J Pharmacol*. 2000; 32: 357-360.